Gene: QKI

9444
Hqk|QK|QK1|QK3|hqkI
QKI, KH domain containing RNA binding
protein-coding
6q26
Ensembl:ENSG00000112531 MIM:609590 Vega:OTTHUMG00000015977 UniprotKB:Q96PU8
NG_029604.1
SNP Mapped
0   ANCO-SNPs
ND
0   
NA (AD)  NA (ND)   (Frontal_Cortex)
1.519e-1 (AD)  4.766e-1 (ND)

DNA Methylation

There is no related methylation information for this gene.

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
MTMR100.936
KAT2B0.93
C1orf1980.916
VAMP30.912
EFCAB140.902
IL6ST0.884
SEPT20.883
SNX180.882
MYO60.881
ZNF240.88

Top 10 negatively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
RTP1-0.516
FBLN7-0.505
ADRA1D-0.5
OPRD1-0.497
PRSS12-0.497
ABCC12-0.494
CALHM1-0.489
MCHR1-0.485
OR4F29-0.481
KCNH5-0.47

Drugs/Compounds

    There is no DrugBank record for this gene !

ID Drug Name Action PubMed
C0303702-methoxy-5-(2',3',4'-trimethoxyphenyl)tropone"2-methoxy-5-(2',3',4'-trimethoxyphenyl)tropone results in decreased expression of QKI mRNA"20206263
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of QKI mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of QKI mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of QKI mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of QKI mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of QKI mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of QKI mRNA"27188386
D001151ArsenicArsenic affects the methylation of QKI gene25304211
C006632arsenic trioxidearsenic trioxide results in increased expression of QKI mRNA20458559
D001280AtrazineAtrazine results in decreased expression of QKI mRNA25929836
D001280AtrazineAtrazine results in increased expression of QKI mRNA22378314
D001564Benzo(a)pyreneBenzo(a)pyrene results in decreased expression of QKI mRNA20064835
D004958Estradiol[Estradiol co-treated with Tetrachlorodibenzodioxin] results in decreased expression of QKI mRNA19619570
D004958EstradiolEstradiol results in decreased expression of QKI mRNA19619570
D004958Estradiol[Raloxifene Hydrochloride co-treated with Estradiol] results in increased expression of QKI mRNA21185374
C006780bisphenol Abisphenol A affects the expression of QKI mRNA25181051
C018475butyraldehydebutyraldehyde results in decreased expression of QKI mRNA26079696
D002104CadmiumCadmium results in decreased expression of QKI mRNA23369406
D019256Cadmium ChlorideCadmium Chloride results in increased expression of QKI mRNA26472689
C018021cobaltous chloridecobaltous chloride results in decreased expression of QKI mRNA19320972
D003300Copper[NSC 689534 binds to Copper] which results in increased expression of QKI mRNA20971185
D019327Copper SulfateCopper Sulfate results in increased expression of QKI mRNA19549813
C029892cupric chloridecupric chloride results in increased expression of QKI mRNA17211630
D002945CisplatinCisplatin results in decreased expression of QKI mRNA21151649
D004237DiuronDiuron results in increased expression of QKI mRNA21551480
D004317DoxorubicinQKI protein affects the susceptibility to Doxorubicin16217747
D004791Enzyme Inhibitors[Enzyme Inhibitors results in decreased activity of OGA protein] which results in increased O-linked glycosylation of QKI protein23301498
D005020Ethyl MethanesulfonateEthyl Methanesulfonate results in decreased expression of QKI mRNA23649840
D005557FormaldehydeFormaldehyde results in decreased expression of QKI mRNA23649840
D005557FormaldehydeFormaldehyde results in increased expression of QKI mRNA20655997
D006220HaloperidolHaloperidol results in increased expression of QKI mRNA alternative form19335891
D008741Methyl MethanesulfonateMethyl Methanesulfonate results in decreased expression of QKI mRNA23649840
C008493methylselenic acidmethylselenic acid results in increased expression of QKI mRNA18548127
C558013NSC 689534[NSC 689534 binds to Copper] which results in increased expression of QKI mRNA20971185
D010662Phenylmercuric Acetate"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of QKI mRNA"27188386
D010936Plant ExtractsPlant Extracts results in increased expression of QKI mRNA23557933
D020849Raloxifene Hydrochloride[Raloxifene Hydrochloride co-treated with Estradiol] results in increased expression of QKI mRNA21185374
D015474IsotretinoinIsotretinoin results in increased expression of QKI mRNA20436886
D013629TamoxifenTamoxifen affects the expression of QKI mRNA14699072
D013749Tetrachlorodibenzodioxin[Estradiol co-treated with Tetrachlorodibenzodioxin] results in decreased expression of QKI mRNA19619570
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin affects the expression of QKI mRNA22298810
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin results in decreased expression of QKI mRNA19619570
D019772TopotecanQKI protein affects the susceptibility to Topotecan16217747
D014212TretinoinTretinoin results in decreased expression of QKI mRNA21934132
C012589trichostatin A"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of QKI mRNA"27188386
C012589trichostatin Atrichostatin A results in decreased expression of QKI mRNA24935251
C012589trichostatin Atrichostatin A results in increased expression of QKI mRNA24935251|2627250
C057693troglitazonetroglitazone results in decreased expression of QKI mRNA28973697
D014635Valproic Acid"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of QKI mRNA"27188386
D014635Valproic AcidValproic Acid affects the expression of QKI mRNA25979313
D014635Valproic AcidValproic Acid results in decreased expression of QKI mRNA23179753|2493525
D014635Valproic AcidValproic Acid results in increased expression of QKI mRNA23179753|2627250
D014635Valproic AcidValproic Acid results in increased methylation of QKI gene29154799
C025643vinclozolinvinclozolin affects the expression of QKI mRNA19015723

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO:0003723RNA binding-HDA22681889  
GO:0003729mRNA binding-IEA-  
GO:0005515protein binding-IPI16189514  16713569  22365833  23455924  25416956  27107014  
GO:0017124SH3 domain binding-IEA-  
GO ID GO Term Qualifier Evidence PubMed
GO:0001570vasculogenesis-IEA-  
GO:0006397mRNA processing-IEA-  
GO:0007286spermatid development-IEA-  
GO:0008380RNA splicing-IEA-  
GO:0010628positive regulation of gene expression-IEA-  
GO:0042552myelination-IEA-  
GO:0042692muscle cell differentiation-IEA-  
GO:0042759long-chain fatty acid biosynthetic process-IEA-  
GO:0051028mRNA transport-IEA-  
GO:00611583'-UTR-mediated mRNA destabilization-IEA-  
GO ID GO Term Qualifier Evidence PubMed
GO:0005634nucleus-IEA-  
GO:0005737cytoplasm-IEA-  
KEGG ID KEGG Term
Reactome ID Reactome Term Evidence
R-HSA-1643685DiseaseTAS
R-HSA-5663202Diseases of signal transductionTAS
R-HSA-6802952Signaling by BRAF and RAF fusionsTAS
R-HSA-6802957Oncogenic MAPK signalingTAS

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal